2023 ASCO Annual Meeting

Racial Disparities in Cancer Mortality in Patients With GI Malignancies Following Medicaid Expansion

Andrew S...

Highlights

Adjuvant Ribociclib Plus Endocrine Therapy in Patients With HR+/HER2− Early Breast Cancer: Phase III Results

Lisa Kottschade, APRN, MSN, CNP, FAPO, of the Mayo Clinic, discusses the NATALEE study, which evaluated adjuvant ribociclib + estrogen therapy (ET) in patients with stage II or III HR+/HER2− early breast cancer (EBC) at risk for recurrence, including those with no nodal involvement (N0)...

$Phase II Results of MonumenTAL-1: Talquetamab for Relapsed/Refractory Multiple Myeloma$

Highlights

Phase II Results of MonumenTAL-1: Talquetamab for Relapsed/Refractory Multiple Myeloma

Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma...

Highlights

Durvalumab With Paclitaxel/Carboplatin and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab, and Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer Without a Tumor BRCA1/2 Mutation: Phase III Results

Andrew S...

Highlights

Adjuvant Osimertinib In Patients With Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Final Overall Survival Analysis

Lisa Kottschade, APRN, MSN, CNP, FAPO, of the Mayo Clinic, discusses the planned final overall survival analysis from the ADAURA trial...

Highlights

Subgroup Analysis of Elderly Patients With Diffuse Large B-Cell Lymphoma in the Phase III POLARIX Study

Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses a subgroup analysis of elderly patients enrolled in the phase III POLARIX study...

Highlights

HER2-Expressing Solid Tumors: Efficacy and Safety of Trastuzumab Deruxtecan

Andrew S...

Highlights

New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax

Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax (IVO) is not superior to ibrutinib plus obinutuzumab (IO) for treatment-naive older patients with chronic lymphocytic leukemia in the setting of the COVID-19 pandemic...

Highlights

High-Risk Resected Melanoma: Survival Results With mRNA-4157 and Pembrolizumab in KEYNOTE-942

Lisa Kottschade, APRN, MSN, CNP, FAPO, of the Mayo Clinic, discusses the use of the mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma, which prolonged distant metastasis–free survival compared with pembrolizumab alone...

Advertisement

Current Issue

Vol 15 No 6 Sep/Oct 2024

How Do We Achieve Value-Based, Patient-Centered Care?

Beth Faiman

September 16, 2024

Is it Cellulitis Again? Erythema Concerning for Infection in Children With High-Risk Solid Tumors Who Have a Gastrostomy Tube

Kristen L. Dalton, MSN, RN, CPNP-AC, CPHON, Meredith R. Johnson, MSN, RN, CRNP-AC

September 16, 2024

Carcinoid Heart Disease

Nicole Kuhnly, MS, ACNPC-AG, Jessica Shank Coviello, DNP, APRN, ANP-BC, Catherine A. Kobza, MSN, AGACNP-BC, Et al.

September 16, 2024

Table of Contents Archive

Recent Issues

Volume 15, Number 6 (Sep/Oct 2024)

Volume 15, Number 5 (Jul/Aug 2024)

Volume 15, Number 4 (May/Jun 2024)

Volume 15, Number 3 (Apr 2024)

Issues

Sections

Solid Tumors

Hematologic Malignancies

Issues in Oncology

Supportive Care

Developmental Therapeutics

Live Events

Webinars

Educational Resources

2023 ASCO Annual Meeting

Current Issue

Recent Issues